Drug Trial Radar · NCT06728553
Safety and Efficacy Trial of MTX101 2mg for the Acute Treatment of Migraine in Adults
Last checked: Nov 19, 2026Latest source record: Oct 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
78
Actual
Start
Feb 24, 2025
Primary completion
Jun 27, 2025
Study completion Jul 28, 2025
Sponsor
- Lead sponsor
- Manistee TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if drug MTX101 works to treat acute migraine attacks in adults. It will also learn about the safety of the drug MTX101. The main questions it aims to answer are: Does the drug MTX101 lower headache pain for participants and the need to use a rescue medication? What side effects, if any, do participants have when taking the drug MTX101? Researchers will compare the drug MTX101 to a placebo (a look-alike substance that contains no drug) to see if the drug MTX101 works to treat acute migraine attacks. Participants will: Take the drug MTX101 or a placebo to treat 1 migraine attack with each treatment. Visit the clinic twice and have one phone call over a 4 week period for checkups and tests. Keep a diary of their symptoms and the number of times they use a rescue medication.
Conditions
- Migraine
Interventions
MTX101Drug
One 2 mg sublingual tablet of MTX101
PlaceboDrug
One sublingual tablet of placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety assessment (occurrence of adverse events, treatment emergent adverse events and serious adverse events).Time frame: Treatment emergent adverse event safety assessments will be limited to the first 48 hours after a treated attack.
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Kaizen Brain Center
La Jolla, California
Clinical Research Institute, LLC
Santa Monica, California
Brainstorm Research
Miami, Florida
Synergy Clinical Research/Emerald Coast Center for Neurological Disorders
Pensacola, Florida
DelRicht Research
New Orleans, Louisiana
QUEST Research Institute
Farmington Hills, Michigan
Wasatch Clinical Research
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.